1. Acknowledgement to Referees

   Acknowledgement to Referees Open access 17 November 2020 Pages: 555 - 556

2. How Should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton

   • Laurence S. J. Roope
   • John Buckell
   • Philip M. Clarke

   Commentary Open access 03 September 2020 Pages: 557 - 561

   

3. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

   • Angela Stainthorpe
   • Nigel Fleeman
   • Isabel Syndikus

   Review Article Open access 23 March 2020 Pages: 563 - 574

   

4. Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews

   • Neerav Monga
   • Jamie Garside
   • Christina Loefgren

   Systematic Review Open access 21 March 2020 Pages: 575 - 591

5. Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France

   • Olivier Heinzlef
   • Guillaume Molinier
   • Juliette Longin

   Original Research Article Open access 11 February 2020 Pages: 593 - 603

   

6. Cost Analysis of the Automated Examination of Urine with the Sysmex UN-Series™ in a Spanish Population

   • Óscar Herráez Carrera
   • María Del Monte Jarabo Bueno

   Original Research Article Open access 21 February 2020 Pages: 605 - 613

   

7. A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study

   • Fernando de Andrés-Nogales
   • Miguel Ángel Casado
   • José Martínez-Olmos

   Original Research Article Open access 25 February 2020 Pages: 615 - 624

   

8. Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis

   • Shouki Bazarbashi
   • Edward B. De Vol
   • Michael Iskedjian

   Original Research Article Open access 14 April 2020 Pages: 625 - 633

   

9. Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK

   • Bernd Schweikert
   • Chiara Malmberg
   • Susanne Hartz

   Original Research Article Open access 12 March 2020 Pages: 635 - 648

   

10. Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials

    • Katherine Dick
    • Andrew Briggs
    • Henrik Brandi

    Original Research Article Open access 09 March 2020 Pages: 649 - 655

    

11. Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease

    • Padraig Dixon
    • William Hollingworth
    • Sarah Purdy

    Original Research Article Open access 25 March 2020 Pages: 657 - 667

    

12. The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis

    • Justin Carrico
    • Yang Zhao
    • Simon Lowry

    Original Research Article Open access 26 March 2020 Pages: 669 - 677

    

13. A Corticosteroid-Eluting Sinus Implant Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis: A UK-Based Cost-Effectiveness Analysis

    • Mehdi Javanbakht
    • Hesham Saleh
    • Margaret Boiano

    Original Research Article Open access 12 February 2020 Pages: 679 - 686

    

14. Estimation of the Incremental Cumulative Cost of HIV Compared with a Non-HIV Population

    • Joshua P. Cohen
    • Anne Beaubrun
    • Dionne M. Hines

    Original Research Article Open access 26 March 2020 Pages: 687 - 696

15. Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study

    • Iftekhar Khan
    • Mandy Maredza
    • On behalf of Breathe collaborators

    Original Research Article Open access 02 April 2020 Pages: 697 - 710